Kalaris Therapeutics Inc
KLRS
查看詳細走勢圖
10.060USD
+0.930+10.19%
收盤 12/22, 16:00（美東）報價延遲15分鐘
188.15M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+10.19%
5天
+13.42%
1月
+43.51%
6月
+319.17%
今年開始到現在
+4.14%
1年
+8.27%
查看詳細走勢圖
TradingKey Kalaris Therapeutics Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
Kalaris Therapeutics Inc當前公司基本面數據相對非常健康，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名133/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價17.00。中期看，股價處於上升通道。近一個月，市場表現很強，技術面評分較高，但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Kalaris Therapeutics Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
5
分析師
買入
評級
17.000
目標均價
+175.97%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Kalaris Therapeutics Inc亮點
亮點風險
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Kalaris Therapeutics Inc簡介
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
公司代碼KLRS
公司Kalaris Therapeutics Inc
CEOOxtoby (Andrew)
網址https://kalaristx.com/
常見問題
Kalaris Therapeutics Inc(KLRS)的當前股價是多少？
Kalaris Therapeutics Inc(KLRS)的當前股價是 10.060。
Kalaris Therapeutics Inc 的股票代碼是什麼？
Kalaris Therapeutics Inc的股票代碼是KLRS。
Kalaris Therapeutics Inc股票的52週最高點是多少？
Kalaris Therapeutics Inc股票的52週最高點是12.900。
Kalaris Therapeutics Inc股票的52週最低點是多少？
Kalaris Therapeutics Inc股票的52週最低點是2.140。
Kalaris Therapeutics Inc的市值是多少？
Kalaris Therapeutics Inc的市值是188.15M。
Kalaris Therapeutics Inc的淨利潤是多少？
Kalaris Therapeutics Inc的淨利潤為-58.77M。
現在Kalaris Therapeutics Inc(KLRS)的股票是買入、持有還是賣出？
根據分析師評級，Kalaris Therapeutics Inc(KLRS)的總體評級為買入，目標價格為17.000。
Kalaris Therapeutics Inc(KLRS)股票的每股收益（EPS TTM）是多少
Kalaris Therapeutics Inc(KLRS)股票的每股收益（EPS TTM）是-236.854。
相關品種
+0.44%
+0.43%
+0.45%
+0.21%
+0.60%
+3.60%
+1.22%
+0.04%
-0.10%
+0.10%
-0.31%
+0.90%
+0.82%
-0.25%
-0.02%
+0.71%
+1.48%
0.00%
+1.25%
+1.87%
